Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.

"AV has served as a speaker and consultant from for MSD and Abbvie. EB-M has served as a speaker and consultant for Janssen and Chiesi. LM has served as a speaker and consultant from for MSD, Abbvie, Janssen, Takeda, Pfizer, and Tillots. BG-S, EV, LPL, CP, PG-I, AP, SL, and MJR-L have no conflicts of interest to declare. JB reports personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos. GGK has received honoraria for speaking or consultancy from Abbvie, Janssen, Pfizer, Amgen, and Takeda. He has received research support from Ferring, Janssen, Abbvie, GlaxoSmithKline, Merck, and Shire. He has been a consultant for Gilead. He shares ownership of a patent: Treatment of Inflammatory Disorders, Autoimmune Disease, and PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 September 2018. XC has received grants for research from Abbott, MSD, and Vifor, and fees for advisory board services from Abbott, MSD, Takeda, and Vifor. He has also given lectures for Abbott, MSD, Takeda, Shire, and Allergan."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."

"Trial registration: The study was not previously registered."